Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account
Activity
RulesProposed and final rules open for commentGrantsFederal funding opportunities and deadlinesPress releasesWhat agencies are announcing publiclyHearingsCongressional committee hearings and meetingsBillsLegislation, actions, amendments, and votes
Views
AgenciesEverything from a single federal agencyTopicsActivity grouped by policy areaOrganizationsCompanies, associations, and advocacy groupsCommitteesHouse, Senate, and joint committee activityLegislatorsMembers of Congress, service, bills, and votes
Pricing
LoginCreate account

Table of contents

DetailsRelated

Exhibit 3 - UCSF NDA Label

FDA-2026-P-8558-0005Supporting & Related Material
Document

Details

The document's own metadata, straight from the source system.

Title
Exhibit 3 - UCSF NDA Label
Posted
Aug 4, 2026
Agency
Food and Drug Administration (FDA)
Topics
  • Pharmaceutical Policy
View on regulations.gov ↗
Related

Related documents

Other documents filed with this rulemaking.

View related documents
Supporting & Related Material
Exhibit 1 - JNM Paper (1)
No comment periodAug 4, 2026
Supporting & Related Material
Exhibit 2 - UCLA NDA Label
No comment periodAug 4, 2026
Other
Citizen Petition from University of California, Los Angeles (UCLA)
No comment periodAug 4, 2026
Other
Acknowledgement Letter from FDA DMB to University of California, Los Angeles (UCLA)
No comment periodAug 4, 2026

On this page

DetailsRelated
Government ContextGovernment Context

Track federal rulemaking documents, topics, and agencies — built on primary sources across the federal government.

ActivityRulesGrantsPress releases
ViewsAgenciesTopicsOrganizations
GuidesInstall Government ContextFive questions to ask your agentAll guides
CompanyAboutData sourcesPricing
LegalPrivacyTerms
© 2026 Government Context. Built on primary government sources.Not affiliated with any U.S. government agency.